Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Nutritional and Metabolic Diseases

ClinicalTrials.gov lists 50,125 trials for Nutritional and Metabolic Diseases or a narrower condition beneath it. Novo Nordisk A/S has the most among industry and government lead sponsors, with 1,037.

MeSH D009750 Nutritional and Metabolic Diseases C18
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 3,778 Phase 1/2 Phase 1/2 978 Phase 2 Phase 2 3,836 Phase 2/3 Phase 2/3 645 Phase 3 Phase 3 4,044 Phase 4 Phase 4 3,823 Not applicable Not applicable 21,628 Observational Observational 11,290 Phase 1 Phase 1 3,778 Phase 1/2 Phase 1/2 978 Phase 2 Phase 2 3,836 Phase 2/3 Phase 2/3 645 Phase 3 Phase 3 4,044 Phase 4 Phase 4 3,823 Not applicable Not applicable 21,628 Observational Observational 11,290

Trials per phase (log scale)

2 more sections with rows

67 of the 50,125 trials are tagged with Nutritional and Metabolic Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Nutritional and Metabolic Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Nutritional and Metabolic Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 98 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 2,836

1990: 16 trials (Observational 12, Not applicable 1, Phase 4 1, Phase 2 1, Phase 1/2 1) 1991: 18 trials (Observational 12, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 3) 1992: 32 trials (Observational 13, Not applicable 4, Phase 4 1, Phase 3 6, Phase 2 4, Phase 1/2 1, Phase 1 3) 1993: 29 trials (Observational 15, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 4, Phase 1/2 1, Phase 1 4) 1994: 29 trials (Observational 15, Not applicable 2, Phase 4 1, Phase 3 6, Phase 2 4, Phase 1/2 1) 1995: 45 trials (Observational 20, Not applicable 8, Phase 4 1, Phase 3 4, Phase 2/3 1, Phase 2 9, Phase 1 2) 1996: 43 trials (Observational 18, Not applicable 9, Phase 4 1, Phase 3 7, Phase 2 7, Phase 1/2 1) 1997: 49 trials (Observational 16, Not applicable 8, Phase 4 4, Phase 3 6, Phase 2/3 1, Phase 2 6, Phase 1/2 2, Phase 1 6) 1998: 97 trials (Observational 28, Not applicable 20, Phase 4 6, Phase 3 11, Phase 2 18, Phase 1/2 3, Phase 1 11) 1999: 149 trials (Observational 43, Not applicable 34, Phase 4 5, Phase 3 21, Phase 2/3 3, Phase 2 20, Phase 1/2 2, Phase 1 21) 2000: 214 trials (Observational 49, Not applicable 44, Phase 4 19, Phase 3 48, Phase 2/3 2, Phase 2 31, Phase 1/2 9, Phase 1 12) 2001: 279 trials (Observational 68, Not applicable 58, Phase 4 32, Phase 3 55, Phase 2/3 3, Phase 2 34, Phase 1/2 7, Phase 1 22) 2002: 399 trials (Observational 45, Not applicable 103, Phase 4 71, Phase 3 87, Phase 2/3 10, Phase 2 46, Phase 1/2 6, Phase 1 31) 2003: 579 trials (Other 1, Observational 93, Not applicable 112, Phase 4 113, Phase 3 123, Phase 2/3 22, Phase 2 67, Phase 1/2 13, Phase 1 35) 2004: 789 trials (Observational 124, Not applicable 197, Phase 4 128, Phase 3 164, Phase 2/3 13, Phase 2 91, Phase 1/2 18, Phase 1 54) 2005: 945 trials (Observational 156, Not applicable 230, Phase 4 140, Phase 3 178, Phase 2/3 23, Phase 2 118, Phase 1/2 30, Phase 1 70) 2006: 1,232 trials (Other 1, Observational 208, Not applicable 362, Phase 4 153, Phase 3 217, Phase 2/3 27, Phase 2 144, Phase 1/2 24, Phase 1 96) 2007: 1,431 trials (Other 2, Observational 301, Not applicable 425, Phase 4 162, Phase 3 193, Phase 2/3 32, Phase 2 166, Phase 1/2 29, Phase 1 121) 2008: 1,647 trials (Other 1, Observational 356, Not applicable 485, Phase 4 183, Phase 3 195, Phase 2/3 36, Phase 2 212, Phase 1/2 38, Phase 1 141) 2009: 1,851 trials (Other 1, Observational 398, Not applicable 630, Phase 4 181, Phase 3 186, Phase 2/3 49, Phase 2 178, Phase 1/2 43, Phase 1 185) 2010: 1,830 trials (Observational 398, Not applicable 659, Phase 4 189, Phase 3 175, Phase 2/3 35, Phase 2 148, Phase 1/2 40, Phase 1 186) 2011: 1,885 trials (Observational 373, Not applicable 725, Phase 4 179, Phase 3 197, Phase 2/3 17, Phase 2 170, Phase 1/2 37, Phase 1 187) 2012: 2,020 trials (Observational 447, Not applicable 831, Phase 4 173, Phase 3 179, Phase 2/3 30, Phase 2 162, Phase 1/2 33, Phase 1 165) 2013: 2,010 trials (Observational 395, Not applicable 847, Phase 4 180, Phase 3 190, Phase 2/3 15, Phase 2 146, Phase 1/2 52, Phase 1 185) 2014: 2,129 trials (Other 1, Observational 452, Not applicable 939, Phase 4 182, Phase 3 151, Phase 2/3 30, Phase 2 148, Phase 1/2 46, Phase 1 180) 2015: 2,127 trials (Observational 430, Not applicable 1,014, Phase 4 180, Phase 3 116, Phase 2/3 23, Phase 2 166, Phase 1/2 33, Phase 1 165) 2016: 2,277 trials (Other 1, Observational 532, Not applicable 1,059, Phase 4 195, Phase 3 129, Phase 2/3 35, Phase 2 142, Phase 1/2 31, Phase 1 153) 2017: 2,304 trials (Other 1, Observational 529, Not applicable 1,120, Phase 4 159, Phase 3 127, Phase 2/3 27, Phase 2 140, Phase 1/2 50, Phase 1 151) 2018: 2,396 trials (Observational 526, Not applicable 1,225, Phase 4 158, Phase 3 128, Phase 2/3 23, Phase 2 157, Phase 1/2 34, Phase 1 145) 2019: 2,534 trials (Other 2, Observational 603, Not applicable 1,291, Phase 4 142, Phase 3 138, Phase 2/3 27, Phase 2 136, Phase 1/2 52, Phase 1 143) 2020: 2,120 trials (Other 1, Observational 617, Not applicable 943, Phase 4 112, Phase 3 106, Phase 2/3 21, Phase 2 134, Phase 1/2 34, Phase 1 152) 2021: 2,607 trials (Observational 646, Not applicable 1,305, Phase 4 138, Phase 3 157, Phase 2/3 23, Phase 2 161, Phase 1/2 46, Phase 1 131) 2022: 2,634 trials (Observational 700, Not applicable 1,331, Phase 4 108, Phase 3 127, Phase 2/3 23, Phase 2 129, Phase 1/2 46, Phase 1 170) 2023: 2,754 trials (Observational 667, Not applicable 1,450, Phase 4 121, Phase 3 133, Phase 2/3 22, Phase 2 148, Phase 1/2 51, Phase 1 162) 2024: 2,836 trials (Other 1, Observational 684, Not applicable 1,457, Phase 4 122, Phase 3 135, Phase 2/3 22, Phase 2 142, Phase 1/2 55, Phase 1 218) 2025: 2,749 trials (Observational 630, Not applicable 1,374, Phase 4 125, Phase 3 135, Phase 2/3 21, Phase 2 199, Phase 1/2 46, Phase 1 219)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2,487
2025 2,749
2024 2,836
2023 2,754
2022 2,634
2021 2,607
2020 2,120
2019 2,534
2018 2,396
2017 2,304

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 3,100 trials starting in 2026 and about 2,800 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 10 percent and ran about 4 percent high against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. The part-way figures are from forecasts that used a multiple fitted only on earlier years. A stricter check that trains only on older years did not support adding planned starts for conditions of this size: it ran about 6 percent high against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 3,770 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 33,207 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Nutritional and Metabolic Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 3,778
Phase 1/2 978
Phase 2 3,836
Phase 2/3 645
Phase 3 4,044
Phase 4 3,823
Not applicable 21,628
Observational 11,290
Expanded access 96
Unknown 7

How many Nutritional and Metabolic Diseases trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1,922
Recruiting 4,572
Enrolling by invitation 443
Active, not recruiting 1,714
Available 31

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Nutritional and Metabolic Diseases trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novo Nordisk A/S 1,037
AstraZeneca 569
Eli Lilly and Company 465
Sanofi 386
Merck Sharp & Dohme LLC 294

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Nutritional and Metabolic Diseases? (9)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Semaglutide 407
SITAGLIPTIN 338
LIRAGLUTIDE 318
ATORVASTATIN 278
BMS-512148 254

Showing 5 of 9 drugs.

Start your 14-day trial Email me all 9 drugs as a PDF

Interventions as named in the registry (6)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
1% Metformin 934
Glargine Insulin 625
Exercise 321
Pioglitazone - TZD 247
Empagliflozine 208

Showing 5 of 6 interventions.

Start your 14-day trial Email me all 6 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Nutritional and Metabolic Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Surgical and medical procedures 17,257 4
Pneumonia 11,531 972
Acute MI 11,372 1
Acute Stroke 10,647 1
Heart Failure Hospitalization 10,455 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages